In order to express the F92A/V94A CAV1 mutant in a CAV1-free environment, we generated a CAV1 knockout MDA-MB-231 cell line adapting a modified CRISPR/Cas9 strategy to mitigate heterogeneity observed in cancer cell lines42. This evidence concerns the gene CAV1 and cancer.